Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Status Completed

Clinical Trial Summary

This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the response rate (partial response (PR) and complete response (CR)) in patients with malignant mesothelioma treated with BAY 43-9006.

SECONDARY OBJECTIVES:

I. To determine 3-month failure free survival in patients with malignant mesothelioma treated with BAY 43-9006.

II. To describe the median and overall survival of malignant mesothelioma patients treated with BAY 43-9006.

III. To describe the toxicity profile of BAY 43-9006 in patients with malignant mesothelioma.

IV. To determine whether mesotheliomas contain mutations in exons 11 and 15 of the B-raf gene and correlate these findings with anti-tumor activity of BAY 43-9006.

V. To determine whether the amount of expression of phospho-ERK1/2, as determined by immunohistochemistry from pre-treatment tumor specimens, correlates with anti-tumor activity of BAY 43-9006 in patients with mesothelioma.

VI. To determine whether baseline levels and changes following BAY 43-9006 treatment in angiogenic cytokines (VEGF and PDGF) correlate with anti-tumor activity of BAY 43-9006.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at least every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00107432
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	October 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00025207` - Gefitinib in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00027703` - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma	Phase 2
Terminated	`NCT00028782` - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer	N/A
Recruiting	`NCT04213794` - Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	Early Phase 1
Completed	`NCT01503177` - Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma	Phase 1
Completed	`NCT00243074` - S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT01126346` - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	N/A
Completed	`NCT00039182` - Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung	Phase 2
Withdrawn	`NCT01325753` - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body	N/A
Completed	`NCT00459862` - Pazopanib in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT01064648` - Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma	Phase 1/Phase 2
Completed	`NCT00365053` - PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery	Phase 2
Terminated	`NCT01861301` - Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma	Phase 2
Completed	`NCT00392444` - Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00309946` - Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00030498` - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	Phase 1
Recruiting	`NCT03420963` - Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	Phase 1
Withdrawn	`NCT01105390` - AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.